InCell IT
provides a way to monitor interactions between drug molecule and target proteins
in live human cells.
Magnetic
nanoparticles (MNP) coated with small molecule drugs are delivered into human
cells with fluorescent tagged proteins expressed prior to the delivery. When
the MNPs are delivered into cells, the drug molecules on the surface of MNP
will bind to its interacting targets. An external magnetic field is applied to
give a significant pattern in the cell which would appear as fluorescent
signals when observed with a fluorescent microscope. On the contrary, if the
drug does not bind to the target prepared with a fluorescent tag attached, the
pattern will not give any fluorescent signal.
There
are many different in vitro technology that can do target identification. For
conventional in vitro assays (inhibition assays, affinity purification etc.),
target protein has to be prepared in buffer solution, in modified forms, such
as purified, truncated, or surrogated forms. We assume that such protein in
buffer solution can represent the native protein, but it is not true. The native
protein is a part of the complex cell context, and isolated, modified protein
does not represent the native state. This is one of the reasons why in vitro
assay results sometimes do not correlate to in vivo results. InCell IT
monitors drug-target interaction is human cell, so the biomolecules are exposed
to the environment closer to that of the human body.
Another
advantage of InCell
IT is that it directly visualizes the binding of drug
molecule and target protein. Conventional technology has to employ a third
component to detect the function of the protein, which would imply the binding
of the protein, for example reporter gene. In such case, functionality of the
reporter gene can also play a role in the result therefore false positive or
negative data can be given.
InCell
IT can provide REAL binding in AUTHENTIC environment.
- Target ID
- in vitro ADME/T
- Indication Discovery
- Drug Repositioning